Drug Research
IGBA- 2022 WHO Biosimilar Roadmap Facilitates Accessibility
According to the new whitepaper Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline from the International Generic and Biosimilar Medicines Association (IGBA), the framework provides a fantastic opportunity to re-evaluate how regulatory standards can better progress...
News
Abu Dhabi Airports Joins Pharma.Aero As Strategic Member
As a strategic member representing the Middle East, Abu Dhabi Airports has joined Pharma.Aero, a global member network for life science and medical technology manufacturers, certified cargo communities, and airport operators.
The partnership with Pharma.Aero builds on Abu Dhabi's development...
Drug Research
GHIT Fund Invests ¥790M On Neglected Tropical Disease Items
Two neglected tropical illnesses, lymphatic filariasis and onchocerciasis, will receive a combined investment of about 790-million-yen ($5.3 million) from the Global Health Innovative Technology (GHIT) Fund in Japan.
The parasitic worms that cause lymphatic filariasis, also known as elephantiasis, and...
Clinical Trials
A New Initiative To Assess Clinical Trials Carbon Footprint
The Clinical Trials Environmental Impact Community of Interest (CoI), a cooperative effort that aims to determine the carbon footprint of centralised and decentralised clinical trials, has been launched by The Pistoia Alliance, a non-profit organisation that promotes R&D collaboration...
Clinical Trials
Seven Pharma CEOs Team Together To Accomplish Emission Aims
Seven CEOs of pharmaceutical companies, including GSK, AstraZeneca, Merck, Roche, Novo Nordisk, Samsung Biologics, and Sanofi, have launched a collaborative effort to meet short-term emission reduction goals and hasten the implementation of net zero health systems.
The Sustainable Markets Initiative (SMI) Health...
News
Using Green Pharma Packing To Remove Barriers To Adoption
The majority of consumers base their first impression of a business and its sustainability credentials on the product packaging.
With a third of UK consumers prepared to pay more for sustainable goods and services, the distinction between single-use, non-recyclable, and...
News
OSD Contract Manufacturing Estimated $54.7 Billion By 2030
According to a market analysis, the global oral solid dosage (OSD) contract manufacturing market is forecast to grow $54.7 billion in value by 2030, growing at a compound annual growth rate (CAGR) of 6%.
Oral solids are the most popular...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















